ArticleClinical lung cancer2019
Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers.
Article in Clinical lung cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Stereotactic partial breast irradiation in primary breast cancer: A comprehensive review of the current status and future directions.Frontiers in oncology · 2022Pooled it
- The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.Signal transduction and targeted therapy · 2024Trial
- Lung Stereotactic Body Radiotherapy (SBRT): Challenging Scenarios and New Frontiers.Journal of clinical medicine · 2025Review
- [Advances in the Treatment of Multiple Primary Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Pathophysiology and Management of Chest Wall Pain after Surgical and Non-Surgical Local Therapies for Lung Cancer.JTO clinical and research reports · 2024Review
- Classification of multiple primary lung cancer in patients with multifocal lung cancer: assessment of a machine learning approach using multidimensional genomic data.Frontiers in oncology · 2024Article
- [Recent Advances in Diagnosis and Treatment Strategies for Multiple Primary Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer.Radiation oncology (London, England) · 2023Article
- Real-world comprehensive diagnosis and "Surgery + X" treatment strategy of early-stage synchronous multiple primary lung cancer.Cancer medicine · 2023Article
- Multiple primary lung cancer: Updates of clinical management and genomic features.Frontiers in oncology · 2023Review
- Review
- Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.Journal for immunotherapy of cancer · 2021Article
- Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer.Acta oncologica (Stockholm, Sweden) · 2021Article
- Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.American journal of clinical oncology · 2021Article
- Prognostic outcome after second primary lung cancer in patients with previously treated lung cancer by radiotherapy.Journal of thoracic disease · 2020Article
- Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).Clinical and translational radiation oncology · 2020Article
- Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine.Cancer management and research · 2020Review
- Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPatients with multiple primary lung cancers increasingly receive multiple courses of stereotactic body radiotherapy (SBRT). We aimed to clarify the efficacy and safety of such treatments. PATIENTS AND
methodsWe reviewed a prospective lung SBRT database of patients treated for stage I non-small-cell lung cancer between June 2004 and December 2015.
resultsA total of 374 patients received a single course of SBRT, 14 received synchronous SBRT, 48 received metachronous SBRT alone, and 108 received surgery and metachronous SBRT. Median follow-up was 37.0 months for survivors. Patients who received a single course had a 3-year overall survival (OS) of 54.2% (95% confidence interval [CI], 48.8-59.3), 3-year freedom from progression (FFP) of 67.3% (95% CI, 60.9-72.9), and grade 3 or higher toxicity of 3.5%. Compared to single-course patients, patients receiving metachronous SBRT alone and patients receiving surgery and metachronous SBRT had improved OS (79.7% [95% CI, 64.4-88.9%], P < .0001 and 95.4% [95% CI, 89.2-98.0%], P < .0001, respectively) and FFP (85.8% [95% CI, 70.7-93.5], P = .03 and 95.4% [95% CI, 89.2-98.0%], P < .0001, respectively). Patients receiving synchronous SBRT had similar OS (46.4% [95% CI, 19.3-69.9%], P = .75) and similar FFP (57.5% [95% CI, 25.3-80.0%], P = .17) as single-course patients. There were no significant differences in rates of grade 3 or higher toxicity or of grade 1 or higher toxicity between single-course patients and the other groups.
conclusionPatients who received either synchronous or metachronous SBRT had no significant detriment in OS or toxicity compared to single-course patients. This supports the use of SBRT in patients with multiple primary lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.